Diarrhea – Pipeline Review, Industry Analysis, and Trends Report H2 2017

Posted on 2017-07-18 by Mark Hub in Healthcare // 0 Comments

Market Research HUB

Albany, US, 2017-Jul-18 — /EPR Network/ —Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Diarrhea – Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230587

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diarrhea – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 10, 2, 1, 21 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/diarrhea-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diarrhea – Overview 7
Diarrhea – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Diarrhea – Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Diarrhea – Companies Involved in Therapeutics Development 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
Actelion Ltd 27
Aegis Therapeutics LLC 28
Akthelia Pharmaceuticals Ltd 28
Albireo Pharma Inc 29
Allergan Plc 29
Anatara Lifesciences Limited 30
Ardelyx Inc 30
Assembly Biosciences Inc 31
AzurRx BioPharma Inc 31
Bharat Biotech International Ltd 32
Cosmo Pharmaceuticals NV 32
DiscoveryBiomed Inc 33
GP Pharm SA 33
Miyarisan Pharmaceutical Company Ltd 34
Mucosis BV 34
Napo Pharmaceuticals Inc 35
Nippon Shinyaku Co Ltd 35
Novartis AG 36
Pfizer Inc 36
Prokarium Ltd 37
Rebiotix Inc 37
Recce Ltd 38
RedHill Biopharma Ltd 38
RxBio Inc 39

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1230587

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick